| Overview |
| bs-18235R |
| LGI2 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Cow, Sheep, Pig, Horse, Chicken, GuineaPig |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LGI2 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 55203 |
| Q8N0V4 |
| Secreted |
| KIAA1916; Leucine rich glioma inactivated protein 2; Leucine rich repeat LGI family member 2; Leucine-rich glioma-inactivated protein 2; Leucine-rich repeat LGI family member 2; LGI1 like protein 2; LGI1-like protein 2; LGI2; LGI2_HUMAN; LGIL2. |
| The leucine-rich (LRR) repeat is a 20-30 amino acid motif that forms a hydrophobic Alpha/Beta horseshoe fold, allowing it to accommodate several leucine residues within a tightly packed core. All LRR repeats contain a variable segment and a highly conserved segment, the latter of which accounts for 11 or 12 residues of the entire LRR motif. LGI2 (leucine-rich repeat LGI family, member 2), also known as KIAA1916 or LGIL2, is a 545 amino acid secreted protein that contains four LRR repeats and seven EAR repeats. Expressed in heart, brain and placenta, LGI2 shares high sequence similarity with other LGI family members and is thought to play a role in the pathogenesis of epileptic disorders. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz